Glucotrack Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights
Glucotrack, Inc. reported its 2025 financial results and significant corporate progress including the receipt of three new U.S. patents for its implantable continuous blood glucose monitoring (CBGM) technology, a $4 million private placement, and preparations to file for Investigational Device Exemption (IDE) with the FDA to launch U.S. clinical tr…